GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?,The Lancet Diabetes & Endocrinology

当前位置： X-MOL 学术 › Lancet Diabetes Endocrinol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2020-03-02 , DOI: 10.1016/s2213-8587(20)30043-7
Michael A Nauck ₁ , Juris J Meier ₁

Affiliation

Although the mainstay of glycaemic control in type 1 diabetes has been the replacement of insulin to address the secretory deficiency caused by destruction of β cells, supplementary glucose-lowering treatments such as metformin, amylin analogues, SGLT2 inhibitors, and GLP-1 receptor agonists have been tested in clinical trials hoping for improved efficacy and safety.

中文翻译：